We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Advanced Oncotherapy Plc | LSE:AVO | London | Ordinary Share | GB00BD6SX109 | ORD 25P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.925 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medical Laboratories | 0 | -29.49M | -0.0549 | -0.35 | 10.32M |
TIDMAVO
RNS Number : 9534R
Advanced Oncotherapy PLC
10 November 2021
TR-1: Standard form for notification of major holdings
Hot Features
Premium
1a. Identity of the issuer or the underlying
issuer of existing shares to which voting Advanced Oncotherapy Plc
rights are at- tached ii :
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer
------------------
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights
------------------
An acquisition or disposal of financial instruments
------------------
An event changing the breakdown of voting rights X
------------------
Other (please specify) iii :
------------------
3. Details of person subject to the notification obligation iv
Name Celeste Management SA
------------------------------------------------------------------
City and country of registered office Geneva, Switzerland
(if applicable)
------------------------------------------------------------------
4. Full name of shareholder(s) (if different from 3.) v
Name
------------------------------------------------------------------
City and country of registered office
(if applicable)
------------------------------------------------------------------
5. Date on which the threshold was 24(th) September 2021
crossed or reached vi :
------------------------------------------------------------------
6. Date on which issuer notified 9(th) November 2021
(DD/MM/YYYY):
------------------------------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting rights % of voting rights Total number
at- tached to through financial Total of both of voting rights
shares (to- tal instru- ments in % (8.A + 8.B) held in issuer
of 8. A) (total of 8.B 1 (8.A +
+ 8.B 2) 8.B) vii
---------------------- ---------------------- ---------------------- ------------------
Resulting situation
on the date on
which threshold
was crossed or
reached 6.29% 6.29% 28,333,333
---------------------- ---------------------- ---------------------- ------------------
Position of previous
notification (if
applicable) 8.50% 8.50%
---------------------- ---------------------- ---------------------- ------------------
8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of Number of voting rights ix % of voting rights
shares
ISIN code (if
possible)
---------------------------------------- ---------------------------------------------------------
Direct Indirect Direct Indirect
(DTR5.1) (DTR5.2.1) (DTR5.1) (DTR5.2.1)
------------------ -------------------- ----------------------------------- --------------------
28,333,333 6.29%
------------------ -------------------- ----------------------------------- --------------------
SUBTOTAL 8. A 28,333,333 6.29%
---------------------------------------- ---------------------------------------------------------
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Number of voting
Type of Expiration Exercise/ rights that may be % of voting rights
financial date x Conversion acquired if the instrument
in- strument Period xi is
exercised/converted.
------------------ -------------------- ----------------------------------- --------------------
SUBTOTAL 8. B 1
-------------------- ----------------------------------- --------------------
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R
(1) (b)
Type of Expiration Exercise/ Physical or Number of
financial date x Conversion cash Settlement voting rights % of voting rights
instrument Pe- riod xi xii
------------------- -------------------- ---------------- ----------------- --------------------
SUBTOTAL 8.B.2
---------------- ----------------- --------------------
9. Information in relation to the person subject to the notification
obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled by X
any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the (underlying)
issuer xiii
----------------------------
Full chain of controlled undertakings through which the voting rights
and/or the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity (please add additional
rows as necessary) xiv
----------------------------
% of voting rights % of voting rights Total of both if
if it equals or is through financial it equals or is higher
Name xv higher than the notifiable in- struments if than the notifiable
threshold it equals threshold
or is higher than
the notifiable threshold
--------------------------------- ------------------------------- ------------------------------
10. In case of proxy voting, please identify:
Name of the proxy holder
---------------------------------------------------------------
The number and % of voting rights held
---------------------------------------------------------------
The date until which the voting rights
will be held
---------------------------------------------------------------
11. Additional information xiv
Place of completion Geneva
Date of completion 9(th) November 2021
--------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLURORRAUUAAAA
(END) Dow Jones Newswires
November 10, 2021 06:23 ET (11:23 GMT)
1 Year Advanced Oncotherapy Chart |
1 Month Advanced Oncotherapy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
